Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Alpha Cubed Investments LLC

Alpha Cubed Investments LLC cut its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 586 shares of the medical research company’s stock after selling 41 shares during the period. Alpha Cubed Investments LLC’s holdings in Thermo Fisher Scientific were worth $363,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the stock. Callan Family Office LLC grew its stake in Thermo Fisher Scientific by 21.0% in the third quarter. Callan Family Office LLC now owns 5,022 shares of the medical research company’s stock worth $3,106,000 after purchasing an additional 871 shares in the last quarter. Aprio Wealth Management LLC grew its position in shares of Thermo Fisher Scientific by 9.5% in the 3rd quarter. Aprio Wealth Management LLC now owns 867 shares of the medical research company’s stock worth $536,000 after acquiring an additional 75 shares in the last quarter. Versant Capital Management Inc raised its position in shares of Thermo Fisher Scientific by 15.2% during the 3rd quarter. Versant Capital Management Inc now owns 500 shares of the medical research company’s stock valued at $309,000 after acquiring an additional 66 shares in the last quarter. Atwood & Palmer Inc. lifted its stake in Thermo Fisher Scientific by 0.5% during the third quarter. Atwood & Palmer Inc. now owns 54,557 shares of the medical research company’s stock worth $33,747,000 after purchasing an additional 268 shares during the last quarter. Finally, Security National Bank increased its stake in Thermo Fisher Scientific by 0.4% during the third quarter. Security National Bank now owns 9,924 shares of the medical research company’s stock valued at $6,139,000 after purchasing an additional 38 shares during the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Trading Down 0.6 %

Shares of Thermo Fisher Scientific stock opened at $595.14 on Wednesday. The business has a fifty day simple moving average of $609.35 and a 200-day simple moving average of $582.90. The firm has a market cap of $227.34 billion, a price-to-earnings ratio of 38.17, a price-to-earnings-growth ratio of 3.83 and a beta of 0.77. Thermo Fisher Scientific Inc. has a fifty-two week low of $415.60 and a fifty-two week high of $627.88. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, July 24th. The medical research company reported $5.37 earnings per share for the quarter, beating the consensus estimate of $5.13 by $0.24. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The company had revenue of $10.54 billion during the quarter, compared to analyst estimates of $10.50 billion. During the same quarter last year, the firm posted $5.15 EPS. The business’s revenue for the quarter was down 1.4% on a year-over-year basis. On average, equities analysts forecast that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Friday, September 13th will be paid a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a dividend yield of 0.26%. The ex-dividend date of this dividend is Friday, September 13th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.01%.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on TMO. Royal Bank of Canada reaffirmed an “outperform” rating and set a $767.00 price objective on shares of Thermo Fisher Scientific in a research report on Friday, September 20th. Evercore ISI increased their price target on Thermo Fisher Scientific from $605.00 to $630.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Wells Fargo & Company started coverage on Thermo Fisher Scientific in a research note on Tuesday, August 27th. They set an “overweight” rating and a $670.00 price objective for the company. Morgan Stanley boosted their price target on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the company an “overweight” rating in a report on Friday, September 20th. Finally, Raymond James increased their price objective on shares of Thermo Fisher Scientific from $650.00 to $660.00 and gave the stock an “outperform” rating in a report on Thursday, July 25th. Four investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and an average price target of $653.72.

Insider Buying and Selling

In related news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction on Friday, July 26th. The stock was sold at an average price of $600.85, for a total value of $180,255.00. Following the completion of the transaction, the executive vice president now owns 17,887 shares in the company, valued at $10,747,403.95. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction on Friday, July 26th. The stock was sold at an average price of $600.85, for a total value of $1,201,700.00. Following the completion of the sale, the senior vice president now owns 13,083 shares of the company’s stock, valued at $7,860,920.55. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $600.85, for a total value of $180,255.00. Following the completion of the sale, the executive vice president now directly owns 17,887 shares of the company’s stock, valued at approximately $10,747,403.95. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 23,084 shares of company stock worth $14,094,292 in the last three months. 0.34% of the stock is currently owned by insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.